As winter moves in, COVID-19 cases, hospitalizations and the number of deaths across the world are incredibly rising. In all its various methods, testing is and will be a mainstay for the foreseeable future. However, it is critical to choose the method of testing since the best solution may be not the same during the whole progression of COVID-19.

Bioperfectus takes the lead in developing and producing COVID-19 nucleic acid test kits

Jiangsu Bioperfectus Technologies Co., Ltd. (abbreviated as "Bioperfectus", with stock code "688399") was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on December 5, 2019

Bioperfectus Launches New Product-Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit to Combat COVID-19 Globally

Bioperfectus Novel Corona Virus (SARS-CoV-2) IgM/IgG Rapid Test obtained EU CE certification

HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases.

Influenza and COVID-19 are different diseases caused by completely different viruses. COVID-19 is about 4-5 times as contagious as the flu. It is very important for us to distinguish between these two since it is the first step to determine a therapy solution to the diseases.

It is still a challenging thing for the northern hemisphere encountering "twindemic", a simultaneous COVID-19 and flu outbreak.

Bioperfectus Influenza Real-Time PCR reagent Kit is used to determine the presence of Influenza A or B in a patient's specimen.

Something you have to know about Respiratory Tract Infection...